Novel hyaluronidase PH20 variant with increased enzyme activity

A PH20 variant with specific amino acid substitutions addresses the limitations of recombinant PH20 proteins by enhancing enzyme activity and stability, enabling effective subcutaneous administration of high-molecular-weight drugs through improved hyaluronic acid degradation.

WO2026235290A1PCT designated stage Publication Date: 2026-11-12GENECHEM
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/004963
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-03-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing recombinant PH20 proteins face challenges with low expression efficiency, stability, and enzymatic activity, limiting their use in subcutaneous administration of high-molecular-weight drugs due to the dense extracellular matrix of subcutaneous tissue.

Method used

A PH20 variant with specific amino acid substitutions, such as those in the 177th to 197th and 341st to 353rd positions, enhancing enzyme activity and stability, allowing for improved degradation of hyaluronic acid in subcutaneous tissue.

Benefits of technology

The PH20 variant exhibits superior enzymatic activity and stability, facilitating the subcutaneous administration of high-dose protein drugs and expanding drug diffusion pathways, thus overcoming limitations in existing PH20 proteins.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026004963_12112026_PF_FP_ABST
    Figure KR2026004963_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a novel hyaluronidase PH20 variant. The PH20 variant according to the present invention exhibits excellent functional characteristics due to improved enzyme activity, and thus can be effectively used in an injectable composition, a pharmaceutical composition for cancer treatment, a drug delivery material, or the like.
Need to check novelty before this filing date? Find Prior Art

Description

Novel hyaluronidase PH20 variant with increased enzyme activity

[0001] The present invention relates to a novel human hyaluronidase variant that enhances the enzymatic activity of human hyaluronidase, a hyaluronic acid hydrolyzing enzyme.

[0002] With the recent advancement of biopharmaceuticals, high-performance formulations with large molecular weights, such as antibody therapies and protein drugs, are being actively used in clinical and therapeutic settings. These high-molecular-weight drugs generally require a dosage exceeding a certain amount to act stably within the body, and direct delivery via intravenous injection is the most common method. However, intravenous injection presents limitations in terms of patient convenience and the efficiency of medical resources, as the injection time itself can range from tens of minutes to over an hour.

[0003] As an alternative, subcutaneous injection (SC) is receiving significant attention due to its relatively simple procedure and the possibility of self-administration. Particularly in the treatment of chronic diseases requiring long-term repeated administration, subcutaneous injection plays a crucial role in improving patient compliance by allowing treatment to continue without hospital visits. However, subcutaneous tissue is structurally composed of a dense extracellular matrix, creating an unfavorable environment for the diffusion of high-dose or high-viscosity drugs. Generally, subcutaneous injection is suitable for administering small amounts of 1 to 2 mL; injecting more than 3 mL of liquid can cause swelling, tenderness, and tissue damage at the injection site. These limitations serve as one of the major factors restricting the subcutaneous administration of high-molecular-weight drugs.

[0004] To overcome these permeability limitations, various attempts have been made to expand tissue gaps by temporarily degrading hyaluronic acid, one of the major components of the extracellular matrix. In particular, an enzyme called hyaluronidase plays a role in reducing tissue viscosity and widening drug diffusion pathways by cleaving the β-1,4 bonds of hyaluronic acid. This enzyme is utilized alone for purposes such as alleviating edema, reducing pain, and assisting the diffusion of local anesthetics, and when combined with high-molecular-weight drugs, it can effectively increase the absorption rate and range of the drug.

[0005] It is known that six types of hyaluronidase exist in humans, and among them, PH20 has the characteristic of maintaining activity in neutral to weakly basic (pH 3–8) environments. Thanks to this characteristic, it is attracting attention for its potential as a drug delivery adjuvant. In fact, research and development to produce human PH20 using recombinant technology is actively underway.

[0006] However, existing recombinant PH20 proteins have much room for improvement in terms of expression efficiency, production stability, and enzymatic activity. There are issues such as a rapid decrease in enzymatic activity under specific processing conditions or low yields during the production process; consequently, there is a continuously increasing industrial demand for variants capable of mass production while stably maintaining high activity. In particular, if the subcutaneous administration of high-dose protein drugs becomes possible by increasing the degradation rate of hyaluronic acid in subcutaneous tissue, it can provide a major turning point in the drug development strategy itself, along with securing flexibility in formulation design.

[0007] Therefore, there is a growing technical need for novel PH20 variants that maintain the physiological function of hyaluronidase while exhibiting superior enzymatic activity compared to existing wild-type proteins, as well as improved expression levels and stability. In this context, the present invention aims to provide a PH20 variant that overcomes existing limitations and has high potential for industrial application.

[0008] The inventors prepared a PH20 variant with enhanced enzyme activity by substituting a specific amino acid sequence of the wild-type PH20 protein.

[0009] Accordingly, the objective of the present invention is to provide a novel PH20 variant with enhanced enzyme activity.

[0010] Another objective of the present invention is to provide an injectable composition, a pharmaceutical composition for cancer treatment, and a drug delivery material comprising a novel PH20 variant.

[0011] The present invention relates to a PH20 variant in which one or more amino acid substitutions are introduced at specific positions in the amino acid sequence of a wild-type PH20 protein, and it was experimentally confirmed that the enzyme activity of the PH20 variant according to the present invention is significantly enhanced.

[0012] The present invention will be described in more detail below.

[0013]

[0014] One aspect of the present invention is a PH20 variant comprising a mutation in which one or more amino acids are substituted in wild-type hyaluronidase PH20.

[0015] The term “hyaluronidase” as used in this specification is one of the enzymes that decomposes hyaluronic acid, and is a substance that decomposes hyaluronic acid to reduce its viscosity and widen the space between tissues.

[0016] The term “PH20” in this specification is an enzyme that cleaves the β-1,4 bond between acetylglucosamine and glucuronic acid of hyaluronic acid. Currently, commercially widely used PH20 is in the form extracted from the testes of cattle or sheep, and includes ampadase (bovine hyaluronidase) and vitrase (sheep hyaluronidase), among others, and rHuPH20, pegylated rHuPH20, etc. are used, but are not limited thereto.

[0017] rHuPH20 is a recombinant hyaluronidase based on the human-derived PH20 gene. It has high biocompatibility and low immunogenicity, making it suitable for use as a subcutaneous adjuvant.

[0018] The term “variant” as used herein refers to a polypeptide in which one or more amino acids are conservatively substituted and / or modified, resulting in a sequence of amino acids different from that of the variant prior to modification, while retaining functions or properties. Such variants can generally be identified by modifying one or more amino acids in the amino acid sequence of the polypeptide and evaluating the properties of the modified polypeptide. That is, the capabilities of the variant may be increased, unchanged, or decreased compared to the polypeptide prior to modification. Additionally, some variants may include variants in which one or more parts, such as an N-terminal leader sequence or a transmembrane domain, have been removed. Other variants may include variants in which a portion of the N- and / or C-terminus of a mature protein has been removed. The term "variant" mentioned above may be used interchangeably with terms such as variant, modification, variant polypeptide, mutated protein, mutation, and variant (in English, modification, modified polypeptide, modified protein, mutant, mutein, divergent, etc.), and is not limited to these terms as long as they are used with the meaning of being mutated.

[0019] Additionally, the variant may include deletions or additions of amino acids that have minimal effect on the properties and secondary structure of the polypeptide. For example, a signal (or leader) sequence involved in co-translational or post-translational protein translocation may be conjugated to the N-terminus of the variant. Additionally, the variant may be conjugated with another sequence or linker to enable identification, purification, or synthesis.

[0020] In one embodiment of the present invention, a PH20 variant was produced comprising one or more mutations among a mutation in which all or part of the amino acids within the amino acid range of the 177th to 197th amino acids of the wild form PH20 of SEQ ID NO. 1 are substituted with the amino acid sequence of the 160th to 180th amino acids of Hyal1 of SEQ ID NO. 2, or a mutation in which all or part of the amino acids within the amino acid range of the 341st to 353rd amino acids of SEQ ID NO. 1 are substituted (see Example 1).

[0021] In one embodiment of the present invention, the protein expression and enzyme activity of PH20 variants were compared, comprising a mutation in which all or part of the amino acids within the amino acid range of the 177th to 197th positions of the wild type PH20 of SEQ ID NO. 1 were substituted with the amino acid sequence of the 160th to 180th positions of Hyal1 of SEQ ID NO. 2. As a result of the experiment, some variants (GCP-173, GCP-174) showed levels of expression and enzyme activity similar to the wild type, while the expression of the others was significantly inhibited, confirming that protein expression is sensitively affected by the domain swiping position (see Example 2 and Fig. 1).

[0022] In one embodiment of the present invention, the enzymatic activity of a PH20 variant comprising a mutation in which all or part of the amino acids within the amino acid range of the 177th to 197th positions of the wild-type PH20 of SEQ ID NO. 1 were substituted with the amino acid sequence of the 160th to 180th positions of Hyal1 of SEQ ID NO. 2 was compared with that of the PH20 variant comprising the I344N substitution mutation of SEQ ID NO. 1. Experimental results confirmed that the PH20 variant exhibited superior enzymatic activity compared to the wild-type PH20. Furthermore, the addition of the I344N substitution mutation of SEQ ID NO. 1 showed an increase in enzymatic activity similar to that of the domain-swapped PH20 variants of Example 2 (see Example 3 and Fig. 2).

[0023] In one embodiment of the present invention, the enzymatic activity of a PH20 variant comprising a mutation in which all or part of the amino acids within the amino acid range of the 177th to 197th positions of the wild-type PH20 of SEQ ID NO. 1 were substituted with the amino acid sequence of the 160th to 180th positions of Hyal1 of SEQ ID NO. 2, and the I344Q substitution mutation of SEQ ID NO. 1 was compared. Experimental results confirmed that the PH20 variant exhibited superior enzymatic activity compared to the wild-type PH20. Furthermore, the addition of the I344Q substitution mutation of SEQ ID NO. 1 showed a superior increase in enzymatic activity compared to the domain-swapped PH20 variants of Example 2 (see Example 4 and Fig. 3).

[0024] In one embodiment of the present invention, structural similarity was evaluated for a representative variant (GCP-216) with confirmed enhanced activity by comparing its tertiary structure with that of wild-type PH20. As a result of comparison using AlphaFold 2-based modeling and PyMol, a Tm-score of 0.929 was calculated, indicating very high structural similarity between the two proteins. Through this, it was confirmed that the variant according to the present invention is capable of functional improvement while maintaining structural stability (see Example 5 and Fig. 4).

[0025] The term “PyMOL” in this specification refers to a molecular graphics tool capable of visualizing and analyzing the three-dimensional molecular structure of proteins, etc., and can be used to compare structural similarities between proteins or to identify the spatial location of specific domains.

[0026] The term “TM-score” in this specification is an indicator for numerically evaluating the similarity between two protein structures, having a value between 0 and 1, and generally, a value of 0.5 or higher indicates high structural similarity.

[0027] The PH20 variant according to the present invention may include a mutation in which some or all of the sequences included in the 177th to 196th amino acids of SEQ ID NO. 1 are substituted with the 160th to 179th amino acid sequences of SEQ ID NO. 2.

[0028] Specifically, the PH20 variant of the present invention comprises a mutation in which valine (V), the 177th amino acid of SEQ ID NO. 1, is substituted with proline (P); a mutation in which glutamine (Q), the 178th amino acid of SEQ ID NO. 1, is substituted with aspartic acid (D); a mutation in which leucine (L), the 179th amino acid of SEQ ID NO. 1, is substituted with tryptophan (W); a mutation in which serine (S), the 180th amino acid of SEQ ID NO. 1, is substituted with proline (P); a mutation in which leucine (L), the 181st amino acid of SEQ ID NO. 1, is substituted with alanine (A); a mutation in which threonine (T), the 182nd amino acid of SEQ ID NO. 1, is substituted with proline (P); a mutation in which glutamic acid (E), the 183rd amino acid of SEQ ID NO. 1, is substituted with glutamine (Q); and a mutation in which alanine (A), the 184th amino acid of SEQ ID NO. 1, is substituted with valine Mutation substituted with (V), mutation in which threonine (T), the 185th amino acid of SEQ ID NO. 1, is substituted with glutamate (E), mutation in which glutamate (E), the 186th amino acid of SEQ ID NO. 1, is substituted with alanine (A), mutation in which lysine (K), the 187th amino acid of SEQ ID NO. 1, is substituted with valine (V), mutation in which lysine (K), the 189th amino acid of SEQ ID NO. 1, is substituted with glutamine (Q), mutation in which glutamine (Q), the 190th amino acid, is substituted with aspartic acid (D), mutation in which glutamate (E), the 191st amino acid of SEQ ID NO. 1, is substituted with glutamine (Q), mutation in which glutamate (E), the 193rd amino acid of SEQ ID NO. 1, is substituted with glutamine (Q), mutation in which lysine (K), the 194th amino acid of SEQ ID NO. 1, is substituted with glycine (G) Alternatively, it may include one or more mutations from a group in which the 196th amino acid of sequence number 1, glycine (G), is substituted with alanine (A).

[0029] More specifically, the PH20 variant of the present invention may be one in which the 177th to 196th amino acid sequences of SEQ ID NO. 1 are substituted with PDWPAPQVEAVAQDQFQGAA.

[0030] The PH20 variant according to the present invention may be one in which the 177th to 196th amino acid sequence of SEQ ID NO. 1 is substituted with PDWPAPQVEAVAQDQFQGAA, and the 341st to 353rd amino acid sequence of SEQ ID NO. 1 is X1WX2X3TRTKX4SCQX5.

[0031] Specifically, X1 may be S or T, X2 may be D, E or Q, X3 may be N or Q, X4 may be D, E or K, and X5 may be A, K, L, Q or R, which is a PH20 variant.

[0032] More specifically, X1 may be S or T, X2 may be D, E or Q, X3 may be Q, X4 may be D, E or K, and X5 may be A, K, L, Q or R, which is a PH20 variant.

[0033] More specifically, it may be a PH20 variant in which X1 is S, X2 is D, X3 is Q, X4 is D, and X5 is K or R.

[0034] The PH20 variant according to the present invention may include a polypeptide having at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity with any one of the amino acid sequences of SEQ ID NOs 32 to 52.

[0035] Furthermore, it is obvious that a protein having an amino acid sequence in which some sequences are deleted, modified, substituted, or added is also included within the scope of the present invention, provided that such an amino acid sequence possesses such homology or identity and exhibits efficacy corresponding to the said protein.

[0036] More specifically, the PH20 variant according to the present invention may include any one of the amino acid sequences of SEQ ID NOs 32 to 52.

[0037] Specifically, the PH20 variant according to the present invention may include any one of the amino acid sequences of SEQ ID NOs 40 to 52.

[0038] More specifically, the PH20 variant according to the present invention may include an amino acid sequence of either SEQ ID NO. 47 or 48.

[0039] The term “mutation” as used herein refers to a change in the sequence of nucleotides or amino acids within a gene compared to the wild type. Such mutations include insertions, deletions, substitutions, point mutations, mutations of multiple nucleotides or amino acids, transpositions, inversions, frame shifts, nonsense mutations, or other forms of modification that differentiate a target sequence from the wild-type sequence of the gene.

[0040] The terms “homology” or “identity” as used herein refer to the degree of relationship between two given amino acid sequences or base sequences and may be expressed as a percentage. The terms homology and identity may often be used interchangeably.

[0041] The sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard arrangement algorithms, and a default gap penalty established by the program used may be utilized. Practically, homologous or identical sequences can be hybridized under moderate or high stringent conditions, generally along at least about 50%, 60%, 70%, 80%, or 90% of the entire sequence or its total length. Hybridization also considers polynucleotides containing degenerate codons instead of codons.

[0042] Whether any two polynucleotide or polypeptide sequences have homology, similarity, or identity can be determined using a known computer algorithm, such as the "FASTA" program, using default parameters, for example. Alternatively, it can be determined using the Needleman-Wunsch algorithm, as performed in the Needleman program of the EMBOSS package (version 5.0.0 or later). For example, homology, similarity, or identity can be determined using BLAST from the National Biotechnology Information Database Center or ClustalW.

[0043] Homology, similarity, or identity of polynucleotides or polypeptides can be determined, for example, by comparing sequence information using a GAP computer program. In summary, the GAP program is defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). Default parameters for the GAP program may include (1) a binary comparison matrix (containing values ​​of 1 for identity and 0 for non-identity) and a weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); and (3) no penalty for terminal gaps.

[0044] In addition, whether any two polynucleotide or polypeptide sequences have homology, similarity, or identity can be determined by comparing the sequences through Southern hybridization experiments under defined strict conditions, and the defined appropriate hybridization conditions are within the scope of the art and can be determined by methods well known to those skilled in the art.

[0045] The PH20 variant according to the present invention may comprise one or more substitution mutations of the amino acid sequences mentioned in the present specification from SEQ ID NO. 1, and may be in a form that is cleaved before the phenylalanine (F) residue, which is the 38th amino acid of the N-terminus of SEQ ID NO. 1, and cleaved after the asparagine (N) residue, which is the 483rd amino acid of the C-terminus.

[0046] Another aspect of the present invention is a vector comprising a polynucleotide encoding the amino acid sequence of a PH20 variant according to the present invention.

[0047] Specifically, it may be a vector comprising a polynucleotide encoding the amino acid sequences of SEQ ID NOs 32 to 52.

[0048] More specifically, it may be a vector comprising a polynucleotide encoding the amino acid sequences of SEQ ID NOs 40 to 52.

[0049] More specifically, it may be a vector containing a polynucleotide encoding the amino acid sequence of SEQ ID NO. 47 or 48.

[0050] The term “vector” as used herein means a DNA product containing a sequence of nucleotides of a polynucleotide encoding said target polypeptide, which is operably linked to a suitable expression control region (or expression control sequence) so as to enable the expression of said target polypeptide within a suitable host. The expression control region may include a promoter capable of initiating transcription, any operator sequence for regulating such transcription, a sequence coding for a suitable mRNA ribosome binding site, and a sequence regulating the termination of transcription and translation. After being transformed into a suitable host cell, the vector may replicate or function independently of the host genome and may be incorporated into the genome itself.

[0051] For example, a polynucleotide encoding a target protein can be expressed within a chromosome using a vector for intracellular chromosome insertion. The insertion of said polynucleotide into the chromosome may be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto. A selection marker may be additionally included to confirm whether the chromosome insertion has occurred. The selection marker is intended to select cells transformed by the vector, that is, to confirm whether the target nucleic acid molecule has been inserted, and markers conferring selectable phenotypes such as drug resistance, nutritional requirements, resistance to cytotoxic agents, or the expression of surface proteins may be used. Since only cells expressing the selection marker survive or exhibit other phenotypes in an environment treated with a selective agent, the transformed cells can be selected.

[0052] The vectors used in this application are not particularly limited, and any vector known in the art may be used.

[0053] Examples of vectors commonly used in prokaryotic cells include pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A as phage vectors or cosmid vectors, and pBR-based, pUC-based, pBluescriptII-based, pGEM-based, pTZ-based, pCL-based, and pET-based plasmid vectors. Specifically, pDZ, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC, pDCM2 vectors, etc., can be used.

[0054] As an example of a vector used in eukaryotic cells, yeast expression vectors can be both integrative yeast plasmids (YIp) and extrachromosomal plasmid vectors. The extrachromosomal plasmid vectors may include episomal yeast plasmids (YEp), replicative yeast plasmids (YRp), and yeast centrosome plasmids (YCp). Additionally, artificial yeast chromosomes (YACs) may also be used as vectors for the present application. As a specific example, available vectors are pESCHIS, pESC-LEU, pESC-TRP, pESC-URA, Gateway pYES-DEST52, pAO815, pGAPZ A, pGAPZ B, pGAPZ C, pGAPα A, pGAPα B, pGAPα C, pPIC3.5K, pPIC6 A, pPIC6 B, pPIC6 C, pPIC6α A, pPIC6α B, pPIC6α C, pPIC9K, pYC2 / CT, pYD1 Yeast Display Vector, pYES2, pYES2 / CT, pYES2 / NT A, pYES2 / NT B, pYES2 / NT C, pYES2 / CT, pYES2.1, pYES-DEST52, pTEF1 / Zeo, pFLD1, PichiaPinkTM, p427-TEF, p417-CYC, pGAL-MF, p427-TEF, p417-CYC, PTEF-MF, pBY011, pSGP47, pSGP46, pSGP36, pSGP40, ZM552, pAG303GAL-ccdB, pAG414GAL-ccdB, pAS404, pBridge, pGAD-GH, pGAD T7, pGBK T7, pHIS-2, pOBD2, pRS408, pRS410, pRS418, pRS420, pRS428, yeast micron A form, pRS403, pRS404, pRS405, pRS406, pYJ403, pYJ404, Includes, but not limited to, pYJ405 and pYJ406.

[0055] More specifically, the vector in this specification may be pCDNA3.1-Zeo.

[0056] Another aspect of the present invention is a host cell comprising a polynucleotide encoding a PH20 variant according to the present invention.

[0057] Specifically, it may be a host cell comprising a polynucleotide encoding the amino acid sequences of SEQ ID NOs 32 to 52.

[0058] More specifically, it may be a host cell comprising a polynucleotide encoding the amino acid sequences of SEQ ID NOs 40 to 52.

[0059] More specifically, it may be a host cell containing a polynucleotide encoding the amino acid sequence of SEQ ID NO. 47 or 48.

[0060] Another aspect of the present invention is a host cell comprising a vector containing a polynucleotide encoding a PH20 variant according to the present invention.

[0061] Specifically, it may be a host cell comprising a vector containing a polynucleotide encoding the amino acid sequences of SEQ ID NOs 32 to 52.

[0062] More specifically, it may be a host cell comprising a vector containing a polynucleotide encoding the amino acid sequences of SEQ ID NOs 40 to 52.

[0063] More specifically, it may be a host cell containing a vector containing a polynucleotide encoding the amino acid sequence of SEQ ID NO. 47 or 48.

[0064] At this time, the host cell may be obtained by transforming it with a vector containing a polynucleotide encoding a PH20 variant according to the present invention.

[0065] The term “host cell” as used herein refers to a cell into which exogenous nucleic acid has been introduced (including the offspring of such cell). Host cells include “transformants” and “transformed cells,” which include primary transformed cells and offspring derived therefrom, regardless of the number of passages. The offspring may not have a nucleic acid content identical to that of the parent cell, but may contain mutations. Mutant offspring having the same function or biological activity as those selected from the original transformed cell are included herein. Host cells are any type of cell system that can be used to produce the antibody or bispecific antibody of the present invention. Host cells include cultured cells, for example, mammalian cultured cells, such as HEK cells, CHO cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, and include cells contained within genetically modified animals, genetically modified plants, or cultured plant or animal tissues.

[0066] Specifically, it may be CHO (Chinese hamster ovary) cells, but is not limited to this.

[0067] The term "transformation" as used herein means introducing a vector containing a polynucleotide encoding a target protein into a host cell or microorganism so that the protein encoded by said polynucleotide can be expressed within the host cell. The transformed polynucleotide may include all of the following, regardless of whether it is inserted into or located outside the chromosomes of the host cell, as long as it can be expressed within the host cell. Additionally, said polynucleotide includes DNA and RNA encoding the target protein. said polynucleotide may be introduced in any form that can be introduced into the host cell and expressed. For example, said polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a gene structure containing all the elements necessary for self-expression. said expression cassette may typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal operably linked to said polynucleotide. said expression cassette may be in the form of a self-replicating expression vector. In addition, the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence required for expression in the host cell, but is not limited thereto.

[0068] The term “operably connected” as used in this specification means that a promoter sequence and a gene sequence are functionally connected to initiate and mediate the transcription of a polynucleotide encoding the polypeptide of the purpose of this application.

[0069] The method of transforming a vector according to the present invention includes any method of introducing nucleic acid into a cell, and depending on the host cell, a suitable standard technique as known in the art may be selected and performed. Examples include, but are not limited to, electroporation, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method, and lithium acetate-DMSO method.

[0070] Another aspect of the present invention is a method for producing a PH20 variant comprising a culture step of culturing a host cell comprising a polynucleotide encoding the PH20 variant according to the present invention or a vector containing the same.

[0071] The culture step of the present invention is a step for expressing and obtaining a PH20 variant protein from a host cell, and can be performed under appropriate expression conditions.

[0072] In the culture step according to the present invention, cell culture can be performed using methods widely known in the industry.

[0073] For example, it can be carried out by batch culture, continuous culture, fed-batch culture, etc.

[0074] The term “batch culture method” as used in this specification refers to a culture method in which culture is continued until all of the initially supplied raw substrate is consumed, and the concentration of the substrate, the concentration of metabolites, the concentration of cells, etc., continuously changes over time.

[0075] The term “continuous culture method” as used in this specification refers to a culture method that maintains a constant state while continuously supplying nutrients to enable cells in culture to grow continuously and removing waste products or metabolic byproducts.

[0076] The term “batch-fed culture method” as used in this specification refers to a culture method in which a culture medium is supplied intermittently, and in which the amount of substrate supplied can be freely controlled because the substrate in the culture medium is added at an appropriate rate and there is no outflow.

[0077] Another aspect of the present invention is an injectable composition comprising a PH20 variant according to the present invention.

[0078] Specifically, it may be an injectable composition comprising a PH20 variant of SEQ ID NOs 32 to 52.

[0079] More specifically, it may be an injectable composition comprising a PH20 variant of SEQ ID NOs 40 to 52.

[0080] More specifically, it may be an injectable composition comprising a pH 20 variant of SEQ ID NO. 47 or 48.

[0081] The injectable composition according to the present invention may be one or more compositions selected from the group consisting of subcutaneous injection compositions, intramuscular injection compositions, and local anesthetic compositions, but is not limited thereto.

[0082] The term “composition for subcutaneous injection” as used in this specification refers to a component of an injectable preparation for subcutaneous administration. Subcutaneous injection is a method of injecting a drug into the fat layer beneath the skin, allowing the drug to be slowly absorbed to produce a sustained effect. Drugs used for subcutaneous injection may exist in various forms, such as solution, suspension, or emulsion.

[0083] As used herein, the term “composition for intramuscular injection” refers to the compositional components of a drug injected directly into a muscle. Muscle tissue is rich in blood vessels, allowing for rapid absorption of the drug, and some drugs may be designed to provide a sustained-release effect. Intramuscular injections may exist in various forms, such as aqueous solutions, suspensions, and oily formulations.

[0084] The term “local anesthetic” as used in this specification refers to a drug that temporarily blocks or paralyzes sensation by blocking nerve signals in a specific area. Local anesthetics act by blocking the transmission of pain signals through action on nerves and may be used in the form of injections, creams, gels, patches, etc.

[0085] Another aspect of the present invention is a pharmaceutical composition for cancer treatment comprising a PH20 variant according to the present invention.

[0086] Specifically, it may be a pharmaceutical composition for cancer treatment comprising a PH20 variant of SEQ ID NOs 32 to 52.

[0087] More specifically, it may be a pharmaceutical composition for treating cancer comprising a PH20 variant of SEQ ID NOs 40 to 52.

[0088] More specifically, it may be a pharmaceutical composition for cancer treatment comprising a PH20 variant of SEQ ID NO. 47 or 48.

[0089] The term “pharmaceutical composition” as used in this specification means a composition prepared for the purpose of preventing or treating a disease, and may be formulated into various forms according to conventional methods.

[0090] The content of the PH20 variant of the pharmaceutical composition of the present invention can be appropriately adjusted according to the symptoms of the disease, the degree of progression of symptoms, the condition of the patient, etc. For example, it may be 0.0001 to 99.9% by weight or 0.001 to 50% by weight based on the total weight of the composition, but is not limited thereto. The above content ratio is a value based on the dry weight after removing the solvent.

[0091] The pharmaceutical composition according to the present invention may further include a suitable carrier, excipient, and diluent commonly used in the manufacture of pharmaceutical compositions. The excipient may be one or more selected from the group consisting of, for example, diluents, binders, disintegrants, lubricants, adsorbents, humectants, film-coating materials, and controlled-release additives.

[0092] The pharmaceutical composition according to the present invention may be formulated and used in the form of external preparations such as powders, granules, sustained-release granules, enteric granules, liquids, eye drops, oxylic agents, emulsions, suspensions, ethanol tablets, troches, fragrances, limonene adzes, tablets, sustained-release tablets, enteric tablets, sublingual tablets, hard capsules, soft capsules, sustained-release capsules, enteric capsules, pills, tinctures, soft extracts, dry extracts, fluid extracts, injections, capsules, irrigation solutions, warning agents, lotions, pastes, sprays, inhalants, patches, sterile injectable solutions, or aerosols, according to conventional methods, and the external preparations may have formulations such as creams, gels, patches, sprays, ointments, warning agents, lotions, liniments, pastes, or cataplasms.

[0093] Carriers, excipients, and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0094] When formulating, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

[0095] Excipients such as corn starch, potato starch, wheat starch, lactose, sucrose, glucose, fructose, D-mannitol, precipitated calcium carbonate, synthetic aluminum silicate, calcium monohydrogen phosphate, calcium sulfate, sodium chloride, sodium bicarbonate, refined lanolin, microcrystalline cellulose, dextrin, sodium alginate, methylcellulose, sodium carboxymethylcellulose, kaolin, urea, colloidal silica gel, hydroxypropyl starch, hydroxypropylmethylcellulose, 1928, 2208, 2906, 2910, propylene glycol, casein, calcium lactate, primogel, etc., as additives to tablets, powders, granules, capsules, pills, and lozenges according to the present invention; Gelatin, gum arabic, ethanol, agar powder, cellulose phthalate, carboxymethylcellulose, calcium carboxymethylcellulose, glucose, purified water, sodium casein, glycerin, stearic acid, sodium carboxymethylcellulose, sodium methylcellulose, methylcellulose, microcrystalline cellulose, dextrin, hydroxycellulose, hydroxypropyl starch, hydroxymethylcellulose, refined shellac, starch paste, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, etc. may be used as binders, and hydroxypropylmethylcellulose, corn starch, agar powder, methylcellulose, bentonite, hydroxypropyl starch, sodium carboxymethylcellulose, sodium alginate, Calcium carboxymethylcellulose, calcium citrate, sodium lauryl sulfate, anhydrous silica, 1-hydroxypropylcellulose, dextran, ion exchange resin, polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, sodium bicarbonate, polyvinylpyrrolidone, calcium phosphate, gelled starch, gum arabic, amylopectin, pectin, sodium polyphosphate, ethylcellulose, sucrose, magnesium aluminum silicate, D-sorbitol solution, hard anhydrous silica, etc. disintegrants;Lubricants such as calcium stearate, magnesium stearate, stearic acid, hydrogenated vegetable oil, talc, lycopodium pods, kaolin, petroleum jelly, sodium stearate, cocoa paste, sodium salicylate, magnesium salicylate, polyethylene glycol 4000, 6000, liquid paraffin, hydrogenated soybean oil (Lubri wax), aluminum stearate, zinc stearate, sodium lauryl sulfate, magnesium oxide, macrogol, synthetic aluminum silicate, anhydrous silica, higher fatty acids, higher alcohols, silicone oil, paraffin oil, polyethylene glycol fatty acid ether, starch, sodium chloride, sodium acetate, sodium oleate, dl-leucine, and hard anhydrous silica may be used.

[0096] As additives to the liquid formulation according to the present invention, water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, monostearic acid sucroses, polyoxyethylene sorbitol fatty acid esters (tween esters), polyoxyethylene monoalkyl ethers, lanolin ethers, lanolin esters, acetic acid, hydrochloric acid, water ammonia, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethylcellulose, sodium carboxymethylcellulose, etc. may be used.

[0097] In the syrup preparation according to the present invention, a solution of white sugar, other sugars or sweeteners, etc. may be used, and if necessary, flavorings, coloring agents, preservatives, stabilizers, suspending agents, emulsifiers, viscosity enhancers, etc. may be used.

[0098] Purified water may be used in the emulsion according to the present invention, and emulsifiers, preservatives, stabilizers, fragrances, etc. may be used as needed.

[0099] In the suspension agent according to the present invention, suspending agents such as acacia, tragacanthus, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, hydroxypropylmethylcellulose, 1828, 2906, and 2910 may be used, and surfactants, preservatives, stabilizers, coloring agents, and fragrances may be used as needed.

[0100] The injectable preparation according to the present invention comprises solvents such as distilled water for injection, 0.9% sodium chloride injection solution, Ringer's injection solution, dextrose injection solution, dextrose + sodium chloride injection solution, PEG, lactated Ringer's injection solution, ethanol, propylene glycol, non-volatile oils—sesame oil, cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristate, and benzene benzoate; solubilizing agents such as sodium benzoate, sodium salicylate, sodium acetate, urea, urethane, monoethylacetamide, butazolidine, propylene glycol, tween, nijungtinamide, hexamine, and dimethylacetamide; and buffers such as weak acids and their salts (acetic acid and sodium acetate), weak bases and their salts (ammonia and ammonium acetate), organic compounds, proteins, albumin, peptone, and gums. It may include isotonic agents such as sodium chloride; stabilizers such as sodium bisulfite (NaHSO3), carbon dioxide gas, sodium metabisulfite (Na2S2O3), sodium sulfite (Na2SO3), nitrogen gas (N2), and ethylenediaminetetraacetic acid; sulfating agents such as sodium bisulfide 0.1%, sodium formaldehyde sulfoxylate, thiourea, disodium ethylenediaminetetraacetic acid, and sodium bisulfite acetone; non-analizing agents such as benzyl alcohol, chlorobutanol, procaine hydrochloride, glucose, and calcium gluconate; and suspending agents such as sodium CMC, sodium alginate, Tween 80, and aluminum monostearate.

[0101] The suppository according to the present invention comprises cocoa dough, lanolin, Witepsol, polyethylene glycol, glycerogelatin, methylcellulose, carboxymethylcellulose, a mixture of stearic acid and oleic acid, Subanal, cottonseed oil, peanut oil, palm oil, cocoa butter + cholesterol, lecithin, lanette wax, glycerol monostearate, Tween or Spandex, Imhausen, monollene (propylene glycol monostearate), glycerin, Adeps solidus, Buytyrum Tego-G, Cebes Pharma 16, hexalide base 95, Cotomar, Hydroccote SP, S-70-XXA, S-70-XX75 (S-70-XX95). Bases such as Hydrokote 25, Hydrokote 711, Idropostal, Massa estrarium (A, AS, B, C, D, E, I, T), Massa-MF, Masupol, Masupol-15, Neosupostal-N, Paramount-B, Suposiro (OSI, OSIX, A, B, C, D, H, L), suppository base type IV (AB, B, A, BC, BBG, E, BGF, C, D, 299), Supostal (N, Es), Wecobi (W, R, S, M, Fs), and Tegestor triglyceride base (TG-95, MA, 57) may be used.

[0102] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., with the extract. In addition to simple excipients, lubricants such as magnesium styrate and talc are also used.

[0103] Liquid preparations for oral administration include suspensions, oral liquids, emulsions, and syrups; in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.

[0104] Another aspect of the present invention is a drug delivery material comprising a PH20 variant according to the present invention.

[0105] Specifically, it may be a drug delivery material comprising a PH20 variant of SEQ ID NOs 32 to 52.

[0106] More specifically, it may be a drug delivery material comprising a PH20 variant of SEQ ID NOs 40 to 52.

[0107] More specifically, it may be a drug delivery material comprising a pH20 variant of SEQ ID NO. 47 or 48.

[0108] The term “drug delivery material” as used in this specification refers to various physical and chemical systems for effectively delivering a drug to a desired site. Drug delivery materials can help a drug reach a target site within the body and be released continuously and stably. Drug delivery materials may exist in various forms, such as liposomes, nanoparticles, hydrogels, and transdermal drug delivery systems.

[0109] The present invention relates to a novel hyaluronidase PH20 variant. Since the PH20 variant according to the present invention exhibits functionally superior characteristics with enhanced enzyme activity, it can be effectively utilized in injectable compositions, pharmaceutical compositions for cancer treatment, or drug delivery materials.

[0110] Figure 1 shows the results of a Western blot to confirm the expression of wild-type PH20 and PH20 variants (GCP-170 to GCP-176) in CHO cells.

[0111] Figure 2 shows the results of a comparative analysis of the enzyme activities of GCP-180 to GCP-187 and GCP-201 to GCP-208.

[0112] Figure 3 shows the results of a comparative analysis of the enzyme activities of GCP-188 to GCP-200 and GCP-209 to GCP-221.

[0113] Figure 4 is a protein tertiary structure model of wild-type PH20 and PH20 variant (GCP-216), with the residue regions of P177 to A196 and S341 to K353 marked in red and blue, respectively, and the substitution positions of the amino acid residues are schematically illustrated.

[0114] A PH20 variant in which the 177th to 196th amino acid sequences of SEQ NO. 1 are substituted with PDWPAPQVEAVAQDQFQGAA, wherein the PH20 variant has the 341st to 353rd amino acid sequences X1WX2X3TRTKX4SCQX5, where X1 is S or T, X2 is D, E or Q, X3 is N or Q, X4 is D, E or K, and X5 is A, K, L, Q or R.

[0115] The present invention will be explained in more detail below through the following examples. However, these examples are merely illustrative of the invention, and the scope of the invention is not limited by these examples.

[0116]

[0117] Example 1. Preparation of PH20 variant

[0118] 1-1. Creation of Cloning Vector

[0119] To produce hyaluronidase, gene synthesis was performed by optimizing codons in GeneScript so that the wild-type PH20 gene sequence could be efficiently expressed in CHO (Chinese hamster ovary) cells from F38 to N483.

[0120] The specific amino acid sequences of wild-type PH20, wild-type Hyal1, HP46 (conventional improved PH20 variants), and the PH20 variant according to the present invention are as shown in Tables 1 to 5 below. In the amino acid sequences of Tables 1 to 5 below, the underlined sections indicate sequence ranges in which substitutions have occurred compared to wild-type PH20, and the amino acids indicated in bold represent the actually substituted residues.

[0121]

[0122]

[0123]

[0124]

[0125]

[0126]

[0127] The PH20 gene was amplified using polymerase chain reaction (PCR) and inserted into the HindIII and XhoI restriction enzyme sites of the pCDNA3.1-Zeo vector. ExpiCHO-S TM For expression in (ThermoFisher, Product No. A29127) cells, human serum albumin was used as the signal peptide instead of the intrinsic signal peptide of PH20, and a 10X His-tag was inserted at the 3'-terminus for protein purification using a HisTrap column.

[0128] The sequences of the primers used for cloning the PH20 variant are shown in Tables 6 to 9. In this case, the sequences of sequence numbers 100 to 101 were used as primers to amplify the PDWPAPQVEAVAQDQFQGAAK sequence.

[0129] Sequence number name amplification Gene sequence number direction Sequence information (5`-3`)531_For1ForGGCTAGCGTTTAAACTTAAGCTT541_Rev 1Rev 1GCCCTCTAGACTCGAGTTAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTTGTAGAAGATCTGTGGCTCTT551_Rev 2Rev 2ACGGGCCCTCTAGACTCGAGTT561_Has ForHas ForTTCAGCTCTGCTTACTCTTTCAGAGCTCCTCCTGTGATA571_Has RevHas RevAGAGTAAGCAGAGCTGAAC58180_For180ForTCTTGGGAGAACACCAGAACCAAAGAATCTTGCCAGAAGCTGGACAACTACATGGAAACCA59180_RevRevCTGGCAAGATTCTTTGGTTCTGGTGTTCTCCCAAGAGCCCCAGATCACGATTCCAG

[0130]

[0131] Sequence number Name Amplification Gene sequence number Directional sequence information (5`-3`)76189_For189ForTCTTGGGAGCAGACCAGAACCAAAGAATCTTGCCAGGCCCTGGACAACTACATGGAA77189_RevRevTTCTTTGGTTCTGGTCTGTCTCCAAGAGCCCCAGATCACGATTCCA78190_For190ForTCTTGGGAGCAGACCAGAACCAAAGAATCTTGCCAGAGACTGGACAACTACATGGAA79190_RevRevTTCTTTGGTTCTGGTCTGTCTCCAAGAGCCCCAGATCACGATTCCA80191_For191ForTCTTGGGAGCAGACCAGAACCAAAGAATCTTGCCAGCAGCTGGACAACTACATGGAA81191_RevRevTTCTTTGGTTCTGGTCTGTCTCCTCCCAAGAGCCCCAGATCACGATTCCA82192_For192ForTCTTGGGAGCAGACCAGAACCAAAGAATCTTGCCAGCTGCTGACAACT ACATGGAA83192_RevRevTTCTTTGGTTCTGGTCTGCTCCCAAGAGCCCCAGATCCACGATTCCA84193_For193ForTCTTGGCAGCAGACCAGAACCAAAAAGTCTTGCCAGAAGCTGGACAACTACATGGAA85193_RevRevCTTTTTGGTTCTGGTCTGCTGCCAAGAGCCCCAGATCACGATTCCAGA86194_For194ForTCTTGGCAGCAGACCAGAACCAAAAAGTCTTGCCAGAGACTGGACAACTACATGGAA87194_RevRevCTTTTTGGTTCTGGTCTGCTGCCAAGAGCCCAGATCACGATTCCAGA88195_For195ForTCTTGGCACACACACAACCAAAGACTCTTGCCCAGAAGCTGGACAACTACATGGAA89195_RevGTCTTTTGGTTCTGGTCTGGTCCCAAGAGCCCCAGATCACGATTCCAGA

[0132] Sequence number name amplification gene sequence number direction sequence information (5`-3`)90196_For196ForTCTTGGGACCAGACCAGAACCAAAGACTCTTGCCAGAGACTGGACAACTACATGGAA91196_RevRevGTCTTTGGTTCTGGTCTGGTCCCAAGAGCCCCAGATCACGATTCCAGA92197_For197ForTGGGAGCAGACCAGAACCAAAGAATCTTGCCAGAAGCTGGACAACTAC ATGGAA93197_RevRevAGATTCTTTGGTTCTGGTCTGCTCCCAGGTGCCCCAGATCACGATT94198_For198ForTGGGAGCAGACCAGAACCAAAGAATCTTGCCAGAGACTGGACAACTACATGGAA95198_RevRevAGATTCTTTGGTTCTGGTCTGCTCCCAGGTGCCCCAGATCACGATT96199_For19 9ForTGGCAGCAGACCAGAACCAAAAAGTCTTGCCAGAAGCTGGACAACTACATGGAA97199_RevRevAGACTTTTTGGTTCTGGTCTGCTGCCAGGTGCCCCAGATCACGATT98200_For200ForTGGGACCAGACCAGAACCAAAGACTCTTGCCAGAAGCTGGACAACTACATGGAA99200_RevRevAGAGT CTTTGGTTCTGGTCTGGTCCCAGGTGCCCCAGATCACGATT100174-F_For174-FForCAGGTGGAAGCCGTGGCCCAGGATCAGTTCCAGGGCGCTGCTAGAGACTTCCTGGTGGAAACCATC101174-F_RevRevCTGGGCCACGGCTTCCACCTGAGGGGCAGGCCAATCAGGGTTCTGCTGTTGGACCAGTTC

[0133] 1-2. Protein Expression

[0134] The expression of the variant was performed using the ExpiCHO expression system. The cell number of ExpiCHO-S cells was 6 x 10 6When the cell count reached cells / mL, the plasmid containing the variant PH20 was inserted into ExpiCHO-S cells using the ExpiFectamine CHO Reagent, and then 25 to 30 ml of cells were cultured with shaking for 4 to 7 days in a 37°C shaker with approximately 80% humidity and 5 to 8% CO2. Upon completion of culture, the cells were centrifuged at 10,000 rpm for 30 minutes to collect the supernatant.

[0135] The expressed protein was confirmed using SDS-PAGE and Western blot, and then filtered through a 0.22 µm filter for purification.

[0136]

[0137] 1-3. Protein Purification

[0138] Purification was performed using a HisTrap HP column. Prior to use, the column was equilibrated using binding buffer (500 mM NaCl, 20 mM sodium phosphate, pH 7.4). The prepared culture medium was flowed through the prepared column to bind the target protein, followed by a wash with binding buffer. Subsequently, to elute the bound target protein, the target protein was selected using the linear gradient method with illusion buffer (500 mM NaCl, 20 mM sodium phosphate, 0.5 M imidazole, pH 7.4). All processes were carried out at a flow rate of 1 to 5 ml / min. The selected target protein was filtered through a 0.2 µm filter, and its activity was measured. Cytiva AKTA pure instruments were used for FPLC.

[0139]

[0140] 1-4. Enzyme Activity Analysis

[0141] The enzymatic activity of hyaluronidase pH 20 and other hyaluronidases was measured using the following Morgan-Elson method.

[0142] The Morgan-Elson method is a colorimetric analysis method that quantifies the red substance produced by the reaction of the reducing end of N-acetyl-D-glucosamine (GlcNAc), which is generated when hyaluronic acid is hydrolyzed by hyaluronidase, with para-dimethylaminobenzaldehyde (DMAB), which is Ehrlich's reagent, by 545 nm absorption. N-acetyl-D-glucosamine (GlcNAc, Sigma) was diluted to concentrations of 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, and 20 mM in dilution buffer solution (0.1 M sodium phosphate, 0.1 M NaCl, 1.3 mg / ml BSA, pH 6.0). Each test tube was treated with tetraborate, heated at 100°C for 5 minutes, and then DMAB was added to induce a color reaction at 37°C for 20 minutes. After the reaction, the absorbance was measured at 545 nm to construct a standard reaction curve for GlcNAc. 5 μl of diluted hyaluronidase solution was added to 125 μl of dilution buffer solution (1.5 mg / ml HA, 0.1 M sodium phosphate, 0.1 M NaCl, 1.5 mM saccharin acid 1,4-lactone, pH 6.0) to form the substrate hyaluronic acid, and the mixture was reacted at 37°C for 45 minutes. The enzyme reaction was then terminated by heating at 100°C for 5 minutes. After adding tetraborate and heating at 100°C for 5 minutes, DMAB was added to allow the color development reaction to proceed at 37°C for 20 minutes. After the reaction, the absorbance was measured at 545 nm, and the enzyme activity was determined using the standard reaction curve of GlcNAc above.

[0143]

[0144] Example 2. Comparative analysis of expression and enzyme activity according to the location of domain swapping in the V177–K197 region

[0145] To confirm the differences in expression and enzyme activity depending on the location of domain swiping, seven PH20 variants (GCP-170 to GCP-176) were prepared as shown in Table 10, in which the V177–K197 region of wild-type PH20 was substituted with the amino acid sequence of the corresponding region of wild-type Hyal1. The experimental method was carried out in the same manner as described in Example 1.

[0146] Sequence No. Name Amino Acid Sequence (177–197) Expression (%) Compared to Wild Type PH20 Enzyme Activity (%) 1 Wild Type PH20 VQLSLTEATEKAKQEFEKAGK100100 Sequence No. Name Amino Acid Sequence (140–160) Wild Type PH20 Contrast expression (%) Enzyme activity (%) 4GCP-170VQLPAPQVEAVAQDQFQGAARN / D10.85GCP-171VQWPAPQVEAVAQDQFQGAARN / D6.56GCP-172VDWPAPQVEAVAQDQFQGAAR7.436.67GCP-173PD WPAPQVEAVAQDQFQGAAR101.8978GCP-174PDWPAPQVEAVAQDQFQGAAK95101.89GCP-175PDWPAPQVEAVAQDQFQGAGKN / D10.610GCP-176PDWPAPQVEAVAQDQFQKAGK7086

[0147] As a result of the experiment, as shown in Figure 1, among the seven PH20 variants corresponding to GCP-170 to GCP-176, the PH20 variants corresponding to GCP-173 and GCP-174 showed similar expression efficiency and enzyme activity compared to wild-type PH20, but the expression of the remaining five PH20 variants was significantly inhibited. Through this, it was found that the location of domain swiping has an important influence on the level of protein expression.

[0148]

[0149] Example 3. Analysis of the synergistic effect of enzyme activity of PH20 variants (GCP-180 to GCP-187) containing I344N amino acid substitution

[0150] To determine whether a PH20 variant containing a domain (PDWPAPQVEAVAQDQFQGAA) in which the amino acid sequences of V177 to G196 of wild-type PH20 are substituted with the corresponding amino acid sequences of P160 to A179 of wild-type Hyal1, and additionally containing an I344N amino acid substitution, can enhance enzyme activity, 9 variants of PH20 (GCP-201 to GCP-208) were each constructed. The experimental method is the same as that described in Example 1.

[0151] As a result of the experiment, the PH20 variants of GCP-201 to GCP-208 showed slightly reduced or similar enzyme activity compared to the PH20 variants of GCP-180 to GCP-187 (Fig. 2).

[0152]

[0153] Example 4. Analysis of the synergistic effect of enzyme activity of PH20 variants (GCP-188 ~ GCP-200) containing I344Q amino acid substitution

[0154] To determine whether enzyme activity can be enhanced when a domain in which the V177 to G196 region of wild-type PH20 is substituted with the PDWPAPQVEAVAQDQFQGAA amino acid sequence derived from wild-type Hyal1 is fused to a PH20 variant containing an I344Q amino acid substitution, 13 PH20 variants (GCP-209 to GCP-221) were each constructed. The experimental method was the same as described in Example 1.

[0155] As a result of the experiment, the PH20 variants of GCP-209 to GCP-221 showed 30–38% higher enzyme activity compared to the PH20 variants of GCP-188 to GCP-200 (Fig. 3).

[0156] Through this, it was confirmed that when a domain in which the V177 to G196 region of wild-type PH20 is substituted with the PDWPAPQVEAVAQDQFQGAA amino acid sequence derived from wild-type Hyal1 is fused to a PH20 variant containing an I344N or I344Q amino acid substitution, enzyme activity is significantly enhanced only in the PH20 variant containing the I344Q amino acid substitution due to the synergistic effect of the two substituted domains.

[0157] The enzymatic activity of the hyaluronidase PH20 variants produced in Examples 2 and 3 is as shown in Tables 11 to 12 below.

[0158] Sequence No. Name Amino Acid Sequence [177–196] / [341–353] Relative Enzyme Activity Compared to Wild Type PH20 (%) Compared to HP46 (%) 1 Wild Type PH20 [VQLSLTEATEKAKQEFEKAG] / [TLSIMRSMKSCLL] 100 Sequence No. Name Amino Acid Sequence [160–179] Relative Enzyme Activity Compared to Wild Type PH20 (%) Compared to HP46 (%) 2 Hyal1 [PDWPAPQVEAVAQDQFQGAA] Sequence No. Name Amino Acid Sequence [304–316] Relative Enzyme Activity Compared to Wild Type PH20 (%) Compared to HP46 (%) 3 HP46 [SWENTRTKESCQA] 289 100 Sequence No. Name Amino Acid Sequence [304–316] Relative Enzyme Activity Wild Type PH20 Contrast (%)HP46Compare (%)11GCP-180[SWENTRTKESCQK]37913112GCP-181[SWENTRTKESCQR]37613013GCP -182[SWQNTRTKKSCQK]30310514GCP-183[SWQNTRTKKSCQR]29210115GCP-184[SWDNTRTKDSCQK]2 839816GCP-185[TWENTRTKESCQK]2809717GCP-186[TWQNTRTKKSCQK]2287918GCP-187[TWDNTRT KDSCQK]2147419GCP-188[SWEQTRTKESCQK]38413320GCP-189[SWEQTRTKESCQA]37312921GCP-19 0[SWEQTRTKESCQR]37613022GCP-191[SWEQTRTKESCQQ]36112523GCP-192[SWEQTRTKESCQL]367 12724GCP-193[SWQQTRTKKSCQK]35512325GCP-194[SWQQTRTCKSCQR]36112526GCP-195[SWDQTRT KDSCQK]34411927GCP-196[SWDQTRTKDSCQR]35012128GCP-197[TWEQTRTKESCQK]2699329GCP-1 98[TWEQTRTKESCQR]2759530GCP-199[TWQQTRTKKSCQK]2639131GCP-200[TWDQTRTKDSCQK]25488

[0159]

[0160] Example 5. Comparison of protein tertiary structures of wild-type PH20 and PH20 variant (GCP-216)

[0161] To determine the relative positions of the P177 to A196 domains substituted with the wild-type Hyal1 amino acid sequence of the PH20 variant (GCP-216) produced in the present invention, the tertiary structures of the wild-type PH20 and the PH20 variant (GCP-216) were compared. As shown in Figure 4, the tertiary structure model of PH20 was constructed using the AlphaFold 2 modeling program from DeepMind. When calculating the similarity between the tertiary structures of the wild-type PH20 and the PH20 variant (GCP-216) using the PyMol program, the Tm score was 0.929, indicating that the tertiary structures are very similar.

[0162] The present invention relates to a novel human hyaluronidase variant that enhances the enzymatic activity of human hyaluronidase, a hyaluronic acid hydrolyzing enzyme.

Claims

1. In a PH20 variant in which the 177th to 196th amino acid sequences of SEQ ID NO. 1 are substituted with PDWPAPQVEAVAQDQFQGAA, The above PH20 variant has an amino acid sequence of the 341st to 353rd positions X1WX2X3TRTKX4SCQX5, and The above X1 is S or T; The above X2 is D, E, or Q; The above X3 is N or Q; The above X4 is D, E, or K; and The above X5 is a PH20 variant that is A, K, L, Q, or R.

2. In Paragraph 1, The above X1 is S or T; The above X2 is D, E, or Q; The above X3 is Q and; The above X4 is D, E, or K; and The above X5 is a PH20 variant that is A, K, L, Q, or R.

3. In Paragraph 1, The above X1 is S and; The above X2 is D; The above X3 is Q and; The above X4 is D; and The above X5 is a PH20 variant that is K or R.

4. In Paragraph 1, The above PH20 variant comprises an amino acid sequence having 95% or more sequence homology with any one of SEQ ID NOs 32 to 52.

5. In Paragraph 1, The above PH20 variant is a PH20 variant comprising any one of the amino acid sequences of SEQ ID NOs 32 to 52.

6. In Paragraph 1, The above PH20 variant is a PH20 variant that is cleaved before the phenylalanine (F) residue, which is the 38th amino acid of the N-terminus of SEQ ID NO. 1, and cleaved after the asparagine (N) residue, which is the 483rd amino acid of the C-terminus.

7. A vector comprising a polynucleotide encoding the PH20 variant of Claim 1.

8. In Paragraph 7, The above vector is a vector that is pCDNA3.1-Zeo.

9. A polynucleotide encoding the PH20 variant of Claim 1; or A vector containing the above polynucleotide; A host cell that includes 10. In Paragraph 9, The above host cell is a CHO (Chinese hamster ovary) cell.

11. A method for producing a PH20 variant comprising a culture step of culturing a host cell comprising a polynucleotide encoding the PH20 variant of claim 1 or a vector comprising said polynucleotide.

12. An injectable composition comprising the PH20 variant of Claim 1.

13. A pharmaceutical composition for treating cancer comprising the PH20 variant of Claim 1.

14. A drug delivery material comprising a pH 20 variant of Claim 1.